Top Markets
Coin of the day
StageZero Life Sciences Ltd. StageZero Life Sciences Ltd.

StageZero Life Sciences Ltd.

SZLS
Rankning i aktier #36214
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise... StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise specializing in the development and market release of advanced molecular diagnostic tests. These innovative solutions are designed for the proactive detection of diseases and individualized health management, with a particular emphasis on oncology-related conditions across North America. Central to its operations is the proprietary Sentinel Principle platform, which enables the identification of novel biomarkers directly from whole blood samples. Its flagship product, Aristotle, exemplifies this innovation; it's a comprehensive multi-cancer panel that simultaneously screens for numerous cancers from a single blood draw, boasting impressive sensitivity and specificity for each identified malignancy. Beyond Aristotle, the company's portfolio includes ColonSentry, a blood-based test gauging colorectal cancer risk; COVID-19 PCR testing and general blood analysis services; the Prostate Health Index for prostate cancer screening; and BreastSentry, designed to evaluate a woman's susceptibility to breast cancer. Established in 1998, StageZero Life Sciences Ltd. maintains its headquarters in Richmond Hill, Canada.
Aktiekurs
$0.02770208
Senast synkroniserad: 2025-03-10
Marknadsvärde
$2.92M
Förändring (1 dag)
-0.46%
Förändring (1 år)
0.00%
Land
CA
Handel StageZero Life Sciences Ltd. (SZLS)

Kategori

P/S-tal för StageZero Life Sciences Ltd. (SZLS)
P/S-tal per 2026 TTM: 0
Enligt StageZero Life Sciences Ltd. senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 0. I slutet av 2026 hade företaget ett P/S-tal på 0.
Historik för P/S-tal för StageZero Life Sciences Ltd. från 2026 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/S-tal för liknande företag eller konkurrenter